Literatur
Krause A, Rubbert-Roth A (2019) Lungenbeteiligung bei rheumatoider Arthritis. Z Rheumatol 78:228–235
Demoruelle MK, Mittoo S, Solomon JJ (2016) Connective tissue disease-related interstitial lung disease. Best Pract Res Clin Rheumatol 30:39–52
Hyldgaard C, Hilberg O, Pedersen AB et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700–1706
Correla CS, Briones MR, Guo R et al (2019) Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease. Clin Rheumatol 38:1201–1206
Sparks JA, He X, Huang J et al (2019) Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis–associated interstitial lung disease: a prospective cohort study. Arthritis Rheum 71:1472–1482
Tsuchiya Y, Takayanagi N, Sugiura H et al (2011) Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37:1411e7
Fernandez-Diaz C, Loricera J, Castaneda S et al (2018) Abatacept in Patients With Rheumatoid Arthritis and Interstitial Lung Disease: A National Multicenter Study of 63 Patients. Semin Arthritis Rheum 48:22–27
Duarte AC, Porter JC, Leandro MJ (2019) The lung in a cohort of rheumatoid arthritis patients—an overview of different types of involvement and treatment. Baillieres Clin Rheumatol 58:2031–2038
Fragoulis GE, Conway R, Nikiphorou E (2019) Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Baillieres Clin Rheumatol 58:1900–1906
Fischer A, Brown KK, Du Bois RM et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40:640–646
Manfredi A, Cassone G, Furini F et al (2019) Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study. Intern Med J. https://doi.org/10.1111/imj.14670
Flaherty KR, Wells AU, Cottin V et al (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381:1718–1727
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
K. Krüger gibt an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
J. Holle, Neumünster
F. Moosig, Neumünster
Rights and permissions
About this article
Cite this article
Krüger, K. Interstitielle Lungenerkrankung (ILD) – wann und wie behandeln?. Z Rheumatol 79, 780–781 (2020). https://doi.org/10.1007/s00393-020-00829-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-020-00829-9